Sanofi (NASDAQ:SNY) Sees Significant Decrease in Short Interest

Sanofi (NASDAQ:SNY) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 3,740,000 shares, a drop of 17.4% from the November 30th total of 4,530,000 shares. Based on an average daily volume of 2,210,000 shares, the short-interest ratio is presently 1.7 days. Approximately 0.2% of the company’s stock are short sold.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Lantz Financial LLC raised its holdings in Sanofi by 23.2% during the second quarter. Lantz Financial LLC now owns 8,054 shares of the company’s stock worth $391,000 after purchasing an additional 1,518 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Sanofi by 67.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 9,466 shares of the company’s stock valued at $459,000 after purchasing an additional 3,815 shares during the period. Cambridge Investment Research Advisors Inc. raised its stake in shares of Sanofi by 1.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 32,161 shares of the company’s stock worth $1,560,000 after buying an additional 332 shares in the last quarter. Harbour Investments Inc. lifted its holdings in shares of Sanofi by 843.1% in the second quarter. Harbour Investments Inc. now owns 4,687 shares of the company’s stock valued at $227,000 after buying an additional 4,190 shares during the period. Finally, HB Wealth Management LLC boosted its stake in Sanofi by 3.7% during the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after buying an additional 221 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on SNY shares. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Trading Down 1.0 %

Shares of NASDAQ:SNY opened at $48.23 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $49.64 and its 200 day moving average price is $52.03. The company has a market cap of $122.40 billion, a PE ratio of 24.61, a P/E/G ratio of 1.23 and a beta of 0.58. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the company posted $2.55 earnings per share. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. Sell-side analysts anticipate that Sanofi will post 4.06 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.